Similar articles

• New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.

  van der Meijden AP. van der Meijden AP. Prog Clin Biol Res. 1992;378:95-101. Prog Clin Biol Res. 1992. PMID: 1301591 Review. No abstract available.
• BCG in the management of superficial bladder cancer.

  Guinan P, Richardson C, Hanna M, Rubenstein M. Guinan P, et al. Prog Clin Biol Res. 1989;303:447-53. Prog Clin Biol Res. 1989. PMID: 2675002 Clinical Trial.
• [Intravesical chemotherapy of superficial bladder tumors].

  Matsumura Y. Matsumura Y. Gan To Kagaku Ryoho. 1989 Feb;16(2):193-8. Gan To Kagaku Ryoho. 1989. PMID: 2645832 Review. Japanese.
• Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.

  Evans CP. Evans CP. Eur Urol. 2007 Oct;52(4):1129-30. doi: 10.1016/j.eururo.2007.02.064. Eur Urol. 2007. PMID: 17383082 No abstract available.
• [A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].

  Oda H, Seki N, Nabeshima S, Oda T, Nishio S, Yokoyama M, Iwata H, Takeuchi M, Matsumoto A, Terado T, et al. Oda H, et al. Gan To Kagaku Ryoho. 1990 Oct;17(10):2051-5. Gan To Kagaku Ryoho. 1990. PMID: 2221929 Clinical Trial. Japanese.